# Ascorbic Acid and Combination Chemotherapy in Treating Patients With Locally Advanced or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery

> **NCT02896907** · EARLY_PHASE1 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University** · enrollment: 8 (actual)

## Conditions studied

- Pancreatic Adenocarcinoma
- Recurrent Pancreatic Carcinoma
- Stage III Pancreatic Cancer
- Stage IV Pancreatic Cancer
- Unresectable Pancreatic Carcinoma

## Interventions

- **DRUG:** Oxaliplatin
- **DRUG:** Irinotecan Hydrochloride
- **DRUG:** Leucovorin Calcium
- **DRUG:** Fluorouracil
- **DIETARY_SUPPLEMENT:** Ascorbic Acid

## Key facts

- **NCT ID:** NCT02896907
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10-18
- **Primary completion:** 2018-03-22
- **Final completion:** 2019-03
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2025-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02896907

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02896907, "Ascorbic Acid and Combination Chemotherapy in Treating Patients With Locally Advanced or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02896907. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*